Stay updated on Biomarker-Directed Therapy in mCRC Clinical Trial
Sign up to get notified when there's something new on the Biomarker-Directed Therapy in mCRC Clinical Trial page.

Latest updates to the Biomarker-Directed Therapy in mCRC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has been updated to include new drug names related to colorectal cancer treatment, specifically Atezolizumab, Vemurafenib, Bevacizumab, Trastuzumab, Pertuzumab, Cobimetinib, 5-FU/LV, and Capecitabine, while significant details about a clinical trial have been removed.SummaryDifference23%
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check70 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check91 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.5%
Stay in the know with updates to Biomarker-Directed Therapy in mCRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker-Directed Therapy in mCRC Clinical Trial page.